Lantheus Holdings (LNTH) Income from Continuing Operations (2014 - 2026)
Lantheus Holdings (LNTH) posted quarterly Income from Continuing Operations of 118417000.0 for Q1 2026, up 62.34% year-over-year from 72945000.0 in Q1 2025, and down 16.68% quarter-over-quarter from 142118000.0 in Q4 2025.
Lantheus Holdings (LNTH) Income from Continuing Operations (2014 - 2026) Analysis & Trends
Lantheus Holdings (LNTH) has reported Income from Continuing Operations for 13 consecutive years, with 118417000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 62.34% year-over-year to 118417000.0; the TTM figure through Mar 2026 stood at 367061000.0 (up 566.01% YoY), while the FY2025 annual figure was 321589000.0, up 1657.63% from the prior year.
- Income from Continuing Operations retreated to 118417000.0 in Q1 2026 per LNTH's latest filing, from 142118000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 142118000.0 in Q4 2025 and bottomed at 344878000.0 in Q4 2024.
- Historically, Income from Continuing Operations has averaged 45416000.0 across 5 years, with a median of 72945000.0 in 2025.
- On a YoY basis, Income from Continuing Operations climbed as much as 4769.26% in 2024 and fell as far as 440.24% in 2024.
- Lantheus Holdings' Income from Continuing Operations stood at 119185000.0 in 2022, then soared by 185.05% to 101364000.0 in 2023, then tumbled by 440.24% to 344878000.0 in 2024, then jumped by 141.21% to 142118000.0 in 2025, then slipped by 16.68% to 118417000.0 in 2026.
- Business Quant data shows LNTH's Income from Continuing Operations at 118417000.0 in Q1 2026, 142118000.0 in Q4 2025, and 27771000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Lantheus Holdings | 6.52 Bn | 5.93 Bn | 241.86 Mn | 75.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 75.03 Mn |
| Mar 31, 2026 | 118.42 Mn |
| Dec 31, 2025 | 142.12 Mn |
| Sep 30, 2025 | 27.77 Mn |
| Jun 30, 2025 | 78.76 Mn |
| Mar 31, 2025 | 72.95 Mn |
| Dec 31, 2024 | -344.88 Mn |
| Sep 30, 2024 | 131.09 Mn |
| Jun 30, 2024 | 62.07 Mn |
| Mar 31, 2024 | 131.07 Mn |
| Dec 31, 2023 | 101.36 Mn |
| Sep 30, 2023 | 131.96 Mn |
| Jun 30, 2023 | 94.13 Mn |
| Mar 31, 2023 | -2.81 Mn |
| Dec 31, 2022 | -119.19 Mn |
| Sep 30, 2022 | 61.23 Mn |
| Jun 30, 2022 | 43.06 Mn |
| Mar 31, 2022 | 42.96 Mn |
| Dec 31, 2021 | -40.22 Mn |
| Sep 30, 2021 | -13.42 Mn |